Status:
ACTIVE_NOT_RECRUITING
Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa
Lead Sponsor:
Sanofi
Conditions:
Glycogen Storage Disease Type II
Eligibility:
All Genders
Up to 12 years
Phase:
PHASE3
Brief Summary
This is a single group, treatment, Phase 3, open-label study to assess efficacy, safety, pharmacokinetic (PK), pharmacodynamics (PD) of avalglucosidase alfa in treatment-naïve male and female particip...
Detailed Description
Study duration may be variable by country, including at least completion of the PAP and ETP, and up to 4.08 years.
Eligibility Criteria
Inclusion
- Participants must have confirmed diagnosis of infantile-onset Pompe disease defined as: the presence of 2 lysosomal acid α-glucosidase (GAA) pathogenic variants and a documented GAA deficiency from blood, skin, or muscle tissue; or the presence of 1 GAA pathogenic variant and a documented GAA deficiency from blood, skin and muscle tissue in 2 separate samples (from either 2 different tissues or from the same tissue but at 2 different sampling dates).
- Participants must have established cross-reactive immunological material (CRIM) status available prior to enrollment.
- Participants must have cardiomyopathy at the time of diagnosis: ie, left ventricular mass index (LVMI) equivalent to mean age specific LVMI
- +1 standard deviation for participants diagnosed by newborn screening or sibling screening;
- +2 standard deviation for participants diagnosed by clinical evaluation.
- Parents or legally authorized representative(s) must be capable of giving signed informed consent.
Exclusion
- Participants with symptoms of respiratory insufficiency, including any ventilation use (invasive or noninvasive) at the time of enrollment.
- Participants with major congenital abnormality.
- Participants with clinically significant organic disease (with the exception of symptoms relating to Pompe disease).
- Participant received any Pompe disease specific treatment, eg enzyme-replacement gene therapy (ERT).
- Participant who has previously been treated in any clinical trial of avalglucosidase alfa.
- Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Key Trial Info
Start Date :
September 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 10 2027
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT04910776
Start Date
September 1 2021
End Date
August 10 2027
Last Update
March 13 2025
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford Hospital- Site Number : 8400006
Stanford, California, United States, 94305
2
Children's Hospitals and Clinics of Minnesota- Site Number : 8400008
Minneapolis, Minnesota, United States, 55404
3
Advanced Medical Genetics- Site Number : 8400002
Hawthorne, New York, United States, 10532
4
Duke University Medical Center- Site Number : 8400004
Durham, North Carolina, United States, 27710